Can a Genomic Test — Spare You Chemotherapy?

The TAILORx trial found that postmenopausal women with an intermediate recurrence score did not benefit significantly from adding chemotherapy to hormone therapy. For premenopausal women, some intermediate scores did show a benefit — the result is more nuanced. Your oncologist will interpret the number in the context of your age, menopausal status, and other tumour features. An intermediate score is not a failed test. It narrows the decision to a clinical conversation where your specific circumstances matter most.

No, and this is an important distinction. A low score means chemotherapy is unlikely to add meaningful benefit beyond hormone therapy for your tumour type. It does not mean the cancer cannot return. You still need hormone therapy and regular follow-up. What the score tells you is that adding chemotherapy would carry its real side effects without a proportionate benefit for your specific tumour biology — not that you are free of all risk.

No. Genomic recurrence-score testing analyses gene activity inside your tumour cells to predict how the cancer is likely to behave and whether it will respond to chemotherapy. It is a test of the tumour. BRCA and hereditary cancer gene tests analyse your own DNA — from a blood or saliva sample — to identify inherited variants that raise your lifetime risk of cancer. Both are valid and answer different questions. Having one done does not mean the other is irrelevant to you.

Yes. If your diagnosis fits — early-stage, hormone receptor-positive, HER2-negative breast cancer and chemotherapy is being discussed — ask directly: 'Is a genomic recurrence-score test like Oncotype DX or MammaPrint applicable for my case?' Your oncologist will tell you whether it applies and, if not, why. Awareness and ordering pathways for these tests vary across India, and not every centre routinely raises them. Asking is how eligible patients learn the option exists.

This is a real barrier for many patients in India, and a few options are worth exploring before concluding it is out of reach. Ask your insurer whether genomic testing is covered — the landscape is changing and some plans now include it. Ask the hospital billing team whether a payment plan or institutional arrangement is available. Discuss with your oncologist whether your pathology report alone provides enough information to guide the chemotherapy decision. For some patients, the clinical picture without genomic testing leads to the same conclusion.

For patients with one to three positive lymph nodes, ASCO guidance supports using Oncotype DX in guiding the chemotherapy decision. The RxPONDER trial specifically showed that postmenopausal women with one to three positive nodes and a low score did not benefit from adding chemotherapy. For premenopausal women with node involvement, the evidence is more complex. For patients with four or more positive nodes, chemotherapy is generally recommended regardless of the genomic score. Ask your oncologist which of these categories your lymph node status puts you in.